H. Mekonnen

Low-dose paroxetine 7.5 mg for menopausal vasomotor symptoms: two randomized controlled trials

J. Simon, D. Portman, A. Kaunitz, 2013, Menopause.

Polymyxin B hemoperfusion in endotoxemic septic shock patients without extreme endotoxemia: a post hoc analysis of the EUPHRATES trial

S. Bagshaw, D. Foster, P. Walker, 2018, Intensive Care Medicine.

Low-dose paroxetine (7.5 mg) improves sleep in women with vasomotor symptoms associated with menopause

J. Pinkerton, J. Lippman, H. Joffe, 2015, Menopause.

Effects of low-dose paroxetine 7.5 mg on weight and sexual function during treatment of vasomotor symptoms associated with menopause

D. Portman, A. Kaunitz, J. Lippman, 2014, Menopause.

PRO 140, a monoclonal antibody targeting CCR5, as a long-acting, single-agent maintenance therapy for HIV-1 infection

S. Badri, Paul J Maddon, D. Burger, 2018, HIV clinical trials.

A novel drug specific mRNA biomarker predictor for selection of patients responding to dovitinib treatment of advanced renal cell carcinoma and other solid tumors.

S. Knudsen, A. Hansen, R. Pili, 2023, PloS one.